P

    Phathom Pharmaceuticals Inc (PHAT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.57
    +0.39 (+4.25%)

    Market Cap: $742.67M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(16/28)
    Avg Surprise
    -2.25%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.04
    Range$-0.01 - $0.07
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$0.05+37.7%
    60d ago$0.05+37.7%
    30d ago$0.05+37.7%
    7d ago$0.04+17.3%
    Current$0.04
    Revenue Consensus
    $85M
    Range$82M - $88M
    9 analysts
    Dec 31, 2026
    EPS Consensus$0.22
    Range$0.14 - $0.29
    4 analysts
    Revenue Consensus
    $102M
    Range$98M - $108M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.22---
    Sep 26EST
    		-$0.04---
    Jun 26
    		$-0.08$-0.15+46.67%Beat+91.1%
    Mar 26
    		$-0.18N/A+53.81%Beat+83.2%
    Dec 25
    		$-0.16$-0.20+20.00%Beat+84.8%
    Sep 25
    		$-0.15N/A+63.41%Beat+85.7%
    Jun 25
    		$-0.90$-0.86-4.65%Miss+28.0%
    Mar 25
    		$-1.07$-1.07-0.38%Miss+3.6%
    Dec 24
    		$-1.05$-1.08+2.78%Beat+24.5%
    Sep 24
    		$-1.05$-1.46+28.08%Beat-38.2%
    Jun 24
    		$-1.25$-1.24-0.81%Miss-48.8%
    Mar 24
    		$-1.11$-1.22+9.02%Beat-24.7%
    Dec 23
    		$-1.39$-1.08-28.70%Miss-4.5%
    Sep 23
    		$-0.76$-0.96+20.83%Beat+42.4%
    Jun 23
    		$-0.84$-0.95+11.58%Beat+36.8%
    Mar 23
    		$-0.89$-1.28+30.47%Beat+16.8%
    Dec 22
    		$-1.33$-1.35+1.48%Beat-40.0%
    Sep 22
    		$-1.32$-1.33+0.75%Beat-34.7%
    Jun 22
    		$-1.33$-1.11-19.82%Miss-33.0%
    Mar 22
    		$-1.07$-1.02-4.90%Miss-11.5%
    Dec 21
    		$-0.95$-1.03+7.77%Beat+39.9%
    Sep 21
    		$-0.98$-1.03+4.85%Beat+3.9%
    Jun 21
    		$-1.00$-0.99-1.01%Miss-56.3%
    Mar 21
    		$-0.96$-1.19+19.33%Beat-54.8%
    Dec 20
    		$-1.58$-1.12-41.07%Miss+60.2%
    Sep 20
    		$-1.02$-0.67-52.24%Miss+72.6%
    Jun 20
    		$-0.64$-0.62-3.23%Miss-
    Mar 20
    		$-0.62$-0.72+13.89%Beat-
    Dec 19
    		$-3.97$-1.25-217.60%Miss-
    Sep 19
    		$-3.72$-3.02-23.18%Miss-

    Key Metrics

    Valuation
    P/E Ratio-16.79EV/EBITDA-2.20x
    Price/FCF-21.71xFCF Yield-4.61%
    Profitability
    Profit Margin-41.30%Operating Margin-5.34%
    ROE-3489.00%ROIC18.25%
    Financial Health
    Debt/Equity-0.48xInterest Coverage-0.65x
    Current Ratio1.92xQuick Ratio1.87x
    Trading Statistics
    Beta0.50Avg Volume1.35M
    52-Week High$18.3152-Week Low$8.21

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.00
    SMA 20$8.89
    SMA 50$10.16
    SMA 200$12.18
    EMA 10$9.08
    EMA 20$9.22
    EMA 50$9.86
    EMA 200$10.95

    MACD

    Line: -0.28Signal: -0.40Hist: 0.12

    ADX

    ADX: 22.9+DI: 20.7-DI: 20.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down28.0
    PSAR$8.47

    Bollinger Bands

    Upper Band$9.70
    Lower Band$8.09
    %B Position1804%(Upper)
    Band Width0.92

    RSI (14-Day)

    Neutral
    52.5

    Momentum Oscillators

    Stoch %K61.7
    Stoch %D47.1
    Williams %R-13.0
    ROC (10d)3.1%
    Momentum0.29
    CCI (20d)116.7
    MFI (14d)72.0

    Volatility Measures

    ATR (14d)$0.55(5.8%)
    StdDev (20d)0.40
    Hist Vol56.8%(High)

    Volume Flow

    VWAP$9.43
    OBV63.0M
    AD Line-15.2M
    CMF (20d)-0.045

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.9x
    VWMA (20d)$8.82

    Pivot Points

    R3$9.92
    R2$9.61
    R1$9.40
    Pivot Point$9.09
    S1$8.87
    S2$8.57
    S3$8.35

    Advanced Oscillators

    TSI-13.23
    Ultimate Osc63.3
    KST-123.07

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$74.27M$58.30M$57.58M$49.50M$39.50M$28.52M$29.66M$16.35M$7.32M$1.91M$682,000$0
    Cost of Revenue$15.10M$12.00M$7.65M$6.19M$5.04M$3.72M$3.81M$2.36M$1.38M$426,000$167,000$0
    Gross Profit$59.18M$46.30M$49.94M$43.31M$34.47M$24.80M$25.85M$14.00M$5.95M$1.49M$515,000$0
    Operating Expenses$63.14M$61.78M$55.87M$58.59M$94.39M$103.66M$85.27M$84.79M$83.25M$71.44M$70.39M$35.66M
    R&D$7.81M$7.77M$7.49M$7.03M$9.08M$9.18M$8.58M$8.69M$7.38M$9.43M$13.39M$12.26M
    SG&A$55.33M$54.01M$48.37M$51.56M$85.31M$94.47M$76.68M$76.10M$75.87M$62.01M$57.00M$23.40M
    Operating Income$-3,965,000$-15,477,000$-5,928,000$-15,271,000$-59,924,000$-78,863,000$-59,417,000$-70,796,000$-77,300,000$-69,954,000$-69,875,000$-35,659,000
    Interest Income$1.51M$1.74M$1.20M$1.41M$1.79M$2.64M$3.51M$3.71M$3.62M$4.31M$3.35M$2.72M
    Interest Expense$15.10M$15.80M$16.42M$16.11M$17.52M$18.07M$18.59M$18.48M$17.76M$17.17M$13.03M$10.11M
    Income Before Tax$-17,582,000$-30,369,000$-21,148,000$-29,973,000$-75,810,000$-94,316,000$-74,451,000$-85,577,000$-91,446,000$-82,852,000$-79,570,000$-43,243,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-17,582,000$-30,369,000$-21,148,000$-29,973,000$-75,810,000$-94,316,000$-74,451,000$-85,577,000$-91,446,000$-82,852,000$-79,570,000$-43,243,000
    EBITDA$-2,963,000$-15,354,000$-4,997,000$-14,347,000$-59,173,000$-78,012,000$-58,546,000$-70,024,000$-76,609,000$-69,309,000$-69,138,000$-35,193,000
    EBIT$-3,989,000$-16,308,000$-5,934,000$-15,278,000$-60,079,000$-78,885,000$-59,368,000$-70,804,000$-77,306,000$-69,997,000$-69,889,000$-35,856,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHAT

    News

    Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2% - What's Next?

    Phathom Pharmaceuticals (NASDAQ:PHAT) saw its shares drop 8.2% to $8.56 in mid-day trading on Thursday, with trading volume significantly lower than average. Despite the recent decline and some analyst price target cuts, the company maintains a "Moderate Buy" consensus rating with an average price target of $22.86. Institutional investors hold a substantial 99.01% stake in the clinical-stage biopharmaceutical company, which focuses on developing GI treatments like vonoprazan.

    MarketBeat•8/20/26•
    Neutral

    3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc.

    Carlyle Group Inc. has acquired a new stake of 3,496,808 shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the second quarter, valued at approximately $37.9 million, making PHAT its third-largest portfolio holding. Institutional investors collectively own 99.01% of the company's stock, with several firms increasing their positions. Despite recent price target reductions, analysts maintain a "Moderate Buy" rating with a consensus target price of $22.86, while the stock recently traded at $9.28.

    MarketBeat•8/18/26•
    Somewhat-Bullish

    PHAT Maintains Overweight Rating -- Price Target Lowered to $14

    Barclays has maintained an "Overweight" rating for Phathom Pharmaceuticals (PHAT) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook despite the company being significantly undervalued according to GuruFocus's GF Value™. The company, which specializes in gastrointestinal treatments, faces financial health and profitability concerns, as indicated by its low GF Score™ of 38/100, and mixed sentiment from institutional investors. Investors are advised to proceed with caution due to ongoing losses and cash flow challenges, even with the potential for an attractive entry point.

    GuruFocus•8/17/26•
    Somewhat-Bearish

    Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

    Phathom Pharmaceuticals (NASDAQ:PHAT) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $22.86, significantly above its current trading price of $9.58. Despite some analysts lowering price targets, most maintain buy ratings, while one firm reaffirmed a sell rating. Institutional investors hold a substantial 99.01% of PHAT shares, and the stock is currently near its 12-month low.

    MarketBeat•8/17/26•
    Somewhat-Bullish

    Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

    Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish on the Voquezna franchise, others have reduced price targets citing lowered revenue guidance and access challenges.

    Yahoo Finance•8/16/26•
    Somewhat-Bearish

    Frequently Asked Questions About PHAT

    Does PHAT pay dividends?
    Phathom Pharmaceuticals Inc (PHAT) does not currently pay a regular dividend.
    What is PHAT's market cap?
    Phathom Pharmaceuticals Inc (PHAT) has a market capitalization of $742.67M with a current stock price of $9.57.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In